Pharmeasy In Talk For Funding With SoftBank Post Thyrocare Deal
- ByStartupStory | July 9, 2021
Pharmeasy in talk for funding with SoftBank. API is seeking a valuation of at least $5.6 billion in a new funding round, said one of the people, who asked not to be identified as the information is private. SoftBank could invest $150 million to $200 million into the online pharmacy owner, the people said. Pharmeasy plans to reach out to other potential investors for the funding round, one of the source said. The company is targeting a listing in the next 12 to 18 months, the source added.
PharmEasy has so far delivered more than 15 million orders from medicine to diagnostic kits to health care products, serving over 5 million families, according to its website.A new round would mean API Holdings is tapping the market shortly after it finished a fundraising exercise. The company completed a Series F round that raised $500 million and valued the firm at nearly $4 billion, its co-founder and Chief Executive Officer Siddharth Shah said on Bloomberg TV on Friday.
Follow Startup Story
Related Posts
